Genotype- or phenotype-based drug formulation
AssigneeBayer Technology Services GmbH
InventorsStefan Willmann, Thomas Eissing, Kristin Dickschen
Life of this patent
Estimating the term…
Abstract
The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (“metabolite”) of the other (“parent substance”), wherein in particular the dosages thereof are selected such that genotypically or phenotypically related variability in the conversion of the parent substance to the metabolite in particular individuals is compensated for.
Claims7
Fixed-dose combination pharmaceutical formulation comprising a parent substance, the action of which is dependent on the quantity or the activity of expressed protein variants, enzyme variants, receptor variants or transporter variants, and at least one metabolite thereof.
Dependencies are inferred from the claim text.